Previous studies of our group have shown that dihydroartemisinin regulates lipid metabolism, TME, and intestinal microflora of the immune microenvironment through YAP1 in HCC, thus enhancing the effect of anti-PD-1 treatment (35–37). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.